Figure 3From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesDurations of response for patients who achieved CR/CRu on romidepsin (IRC). The vertical line separates the 10 patients with long-term responses (duration ≥ 12 months). Of the 2 patients that received stem cell transplant after romidepsin, type of transplant was autologous for 1 patient, and not reported for 1 patient.Back to article page